Dr. Jonathan G. Meiman, MD
Family Medicine (Family Medicine Physician)
At a glance
- In the NPI registry since
- 2010
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
WI license 56800-20
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 5 companies. The companies reported $4,315,710 in research payments for these studies, mostly to the institutions running them.
- Study name not reported
Agios Pharmaceuticals, Inc. - An Open-Label Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants
Incyte Corporation - A Study to Assess the Tolerability and Safety of Subcutaneously (SC) Administered Immunoglobulin G (IgG) With Varying Injection Conditions
Genentech, Inc. - A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis
Sanofi US Services Inc. · Completed · NCT06073093 - A Phase I, Open-Label, Randomised, Two-Period Crossover Study to Investigate the Bioavailability of Single SC Doses of Two Different Formulations in Healthy Subjects
Amgen Inc. - AMG145 - A Phase I, Open-Label, Randomised, Two-Period Crossover Study to Investigate the Bioavailability of Single SC Doses of Two Different Formulations in Healthy Subjects
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.